WO1982000099A1 - Polymeric diffusion matrix for administration of drugs - Google Patents
Polymeric diffusion matrix for administration of drugs Download PDFInfo
- Publication number
- WO1982000099A1 WO1982000099A1 PCT/US1981/000893 US8100893W WO8200099A1 WO 1982000099 A1 WO1982000099 A1 WO 1982000099A1 US 8100893 W US8100893 W US 8100893W WO 8200099 A1 WO8200099 A1 WO 8200099A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- weight
- patient
- diffusion matrix
- sustained release
- polyvinylalcohol
- Prior art date
Links
- 239000011159 matrix material Substances 0.000 title claims abstract description 66
- 238000009792 diffusion process Methods 0.000 title claims abstract description 56
- 229940079593 drug Drugs 0.000 title claims abstract description 39
- 239000003814 drug Substances 0.000 title claims abstract description 39
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 62
- 239000004372 Polyvinyl alcohol Substances 0.000 claims abstract description 26
- 229920002451 polyvinyl alcohol Polymers 0.000 claims abstract description 26
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims abstract description 26
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 22
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 22
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 22
- 238000013268 sustained release Methods 0.000 claims abstract description 19
- 239000012730 sustained-release form Substances 0.000 claims abstract description 19
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims abstract description 18
- 239000004014 plasticizer Substances 0.000 claims abstract description 18
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960000195 terbutaline Drugs 0.000 claims abstract description 13
- 229960001802 phenylephrine Drugs 0.000 claims abstract description 10
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims abstract description 10
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims abstract description 9
- 229940046978 chlorpheniramine maleate Drugs 0.000 claims abstract description 9
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960002179 ephedrine Drugs 0.000 claims abstract description 9
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960002896 clonidine Drugs 0.000 claims abstract description 8
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 claims abstract description 8
- -1 e.g. Substances 0.000 claims abstract description 8
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 claims abstract description 8
- 229960000395 phenylpropanolamine Drugs 0.000 claims abstract description 8
- 150000002159 estradiols Chemical class 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 12
- 230000037317 transdermal delivery Effects 0.000 claims description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims description 10
- 230000002035 prolonged effect Effects 0.000 claims description 10
- 229960005309 estradiol Drugs 0.000 claims description 8
- 229930182833 estradiol Natural products 0.000 claims description 8
- 229940124630 bronchodilator Drugs 0.000 claims description 5
- 239000000850 decongestant Substances 0.000 claims description 4
- 238000012423 maintenance Methods 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 230000001387 anti-histamine Effects 0.000 claims description 2
- 230000003276 anti-hypertensive effect Effects 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 12
- 239000003071 vasodilator agent Substances 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 description 17
- 229920000642 polymer Polymers 0.000 description 7
- 229920000936 Agarose Polymers 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000008240 homogeneous mixture Substances 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 238000013019 agitation Methods 0.000 description 3
- 238000005266 casting Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VQHQLBARMFAKSV-AANPDWTMSA-N [(8r,9s,13s,14s,17s)-3-acetyloxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(OC(C)=O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)C)[C@@]1(C)CC2 VQHQLBARMFAKSV-AANPDWTMSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- GNSFRPWPOGYVLO-UHFFFAOYSA-N 3-hydroxypropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCO GNSFRPWPOGYVLO-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229920002799 BoPET Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000133 nasal decongestant Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
Definitions
- the following methods may be used for preparing the diffusion matrix of the present invention.
- estradiol ester derivatives suitable for use according to this invention are pharmacologically acceptable esters particularly the 3-benzoate and 3-valerate esters of estradiol.
- Estradiol diacetate and other esters of a pharmocologically active type small enough to pass through the skin may also be used.
- the esters suitable for this invention provide a source of pharmacologically active estradiol in the bloodstream. It must also be understood that the estradiol esters contemplated herein may be administered in admixture with other drugs which are not incompatible with the desired therapeutic objective.
- EXAMPLE III In place of the glycerol of Example I, there is substituted 5 gm. polyethylene glycol (mw. 1,000), 4 gm. glycerol and 21 ml. water. The resultant diffusion matrix shares the improved rigidity of the diffusion matrix of Example II, while providing contact with the skin characteristic of the glycerol in this type of diffusion matrix.
Abstract
A polymeric diffusion matrix for administering a drug is provided comprising from about 2 to about 60% of a polar plasticizer, e.g., glycerol, from about6 to about 20% of polyvinylalcohol, from about 2 to about 10% of polyvinylpyrrolidone, and a pharmaceutically effective amount of drug, yielding a matrix capable of sustained release of a vasodilator drug dispersed therein, and the balance water, the percentages being by weight. The drugs include terbutaline, ephedrine, clonidine, phenylephrine, estradiol esters, phenylpropanolamine, and chlorpheniramine maleate.
Description
POLYMERIC DIFFUSION MATRIX FOR ADMINISTRATION OF DRUGS SUMMARY OF THE INVENTION The present invention relates to a polymeric diffusion matrix containing one or more drugs suitable for transdermal administration to a patient. More particularly, the invention relates to a polymeric diffusion matrix containing one or more of such drugs characterized by a sustained relase of such drugs. Among the drugs suitable for administration in the polymeric diffusion matrix of this invention are terbutaline, ephedrine, clonidine, phenylephrine, estradiol esters, phenyl propanolamine, and chlorpheniramine maleate.
A self-supporting polymeric diffusion matrix is provided for the sustained release of a drug or drugs in order to transdermally deliver said drug to a patient, and provide said patient with a therapeutic effect, said matrix comprising from about 2 to about 60% by weight of a polar plasticizer; from about 6 to about 20% by weight polyvinylalcohol; from about 2 to about 10% by weight polyvinylpyrrolidone; and a pharmaceutically effective amount of drug to- provide a sustained release of said drug over a prolonged period.
In one embodiment the polar plasticizer is glycerol present in an amount of from about 2 to about 60% by weight. In another embodiment the polar plasticizer is polyethylene glycol present in an amount of from about 2 to about 15% by weight. A still further embodiment contemplates a mixture of glycerol and polyethylene glycol wherein the latter is present in an amount by weight of from about 1 to about 5 parts per weight glycerol.
The self-supporting polymeric diffusion matrix generally
contains a mixture of polyvinylalcohol and polyvinylpyrrolidone, although it will be understood that other polymeric mixtures may be used provided they yield the desired sustained release effect. For example, both the polyvinylalcohol and the polyvinylpyrrolidone may be completely replaced with from about 1 to about 9% agar or agarose, and preferably from about 1.5 to 3% agar or agarose, 2% agar or agarose being particularly preferred.
As the polyvinylalcohol used in the present invention there is generally contemplated one having a molecular weight from about 50,000 to about 150,000, and more preferably about 100,000 to about 150,000, 115,000 having been used in related systems of the present inventors with success. The polyvinylalcohol should be hydrolyzed, generally at least to the extent of 90%, with a preferred embodiment being at least 95% hydrolyzed. Polyvinylpyrrolidone should have a molecular weight of from about 15,000 to about 85,000, and more preferably from about 20,000 to about 60,000. Polyvinylpyrrolidone with a molecular weight of 40,000 is a particularly preferred embodiment.
The amount by weight of the ingredients other than the polar plasticizer generally should be in the following ranges: polyvinylalcohol is generally present in an amount of from about 6 to about 20% by weight, with 10% being a preferred embodiment; polyvinylpyrrolidone is present generally in an amount of from about 2 to about 10% by weight.
The water-soluble polymer can be replaced with (in addition to agar) gum arabic, gum tragacanth, polyacrylic acid, polymethacryliσ acid, polyvinyloxazolidone, polyvinylmorpholinone, and polyvinylpiperidone.
Polyalkylene glycols such as polyethylene glycol and polypropylene glycol may replace all or part of the glycerol.
It is possible to replace the polyvinylalcohol with polymers of hydroxyethylacrylate, polymers of hydroxyethylmethacrylate, polymers of hydroxypropy1aery1ate, and polymers of
hydroxypropylmethacrylate.
In forming the matrix, excess water is not required. In accordance with a preferred aspect of the present invention, about 2% by weight of any of the drugs listed above are included in the diffusion matrix. The resultant homogeneous mixture is poured into forms preferably made of glass or stainless steel, these forms or templates producing a diffusion matrix having a thickness of about 1 to about 3 mm. in accordance with a preferred aspect of the present invention. This diffusion is either cast or cut into pieces of the desired size.
The following methods may be used for preparing the diffusion matrix of the present invention.
In a first method, the matrix is formed at atmospheric pressure. Water and glycerol are first mixed together.
A polar plasticizer such a glycerol is a necessary component in the matrix. A matrix formed without a polar plasticizer is not flexible and has poor diffusional contact with the skin causing unreliable diffusion release.
The polyvinylalcohol and polyvinylpyrrolidone are then added to the polar plasticizer-water mixture at room temperature, with agitation. The mixture is heated to a temperature within the range of from about 90 to about 95°C at atmospheric pressure to extend the polymers. If desired, the mixture may be maintained at an elevated temperature for a period of time, based on polymer stability, prior to addition of the drug. Thus, the mixture is stable for a period of time and: may be kept for such a period before being mixed with the drug to be delivered to the patient. Thereafter, the mixture is temperature-adjusted and the drug to be applied to the patient is then added to the mixture, with thorough agitation. Once a homogeneous mixture of the polymer solution and drug is obtained, the mixture is ready to be cast to form in a drugcontaining diffusion matrix. After casting the mixture is cooled to a temperature such that gelation occurs. In a
preferred embodiment, the drug may be dissolved by agitation in a suitable solvent such as glycerin and water. The thusobtained solution can be maintained at room temperature for prolonged period without deterioration.
It has been found that curing is facilitated by subjecting the matrix to a temperature down to about -20°C immediately after casting. The setting period is quickened considerably.
Sodium dodecyl sulfate or sorbitan (Tween-20) or other detergents may be added in an amount of 0.1 to 10% by weight, based on the matrix, as a dispersing agent, if desired.
An absorption facilitator to insure skin penetration such as dimethylsulfoxide, decylmethylsulfoxide, or other penetration enhancers may be added.
The present drug delivery device comprises the drugcontaining diffusion matrix and means for fastening the matrix to the skin of a patient. Such means can take various forms, such as an occlusive backing layer forming a kind of "bandage" with the diffusion matrix being held against the skin of a patient being treated. A polyethylene or Mylar tape is contemplated as one form of occlusive layer in accordance with the present invention. It can also take the form of an elastic band, such as a cloth band, a rubbery band or other material. Here, the diffusion matrix is placed directly on the skin and held in place by such elastic band which typically will be placed over the arm or wrist of the patient. An intermediate adhesive layer between the diffusion matrix and the skin capable of permitting the transdermal application of the drug can also be used.
The amount of the drug to be delivered per day to the patient is in each case generally lower that the oral dosage. This is accounted for by the fact that in oral applications much of the drug can be expected to be lost by the first pass through the liver. To assure that the desired quantity of the drug is delivered, an excess of the drug should be
incorporated in the matrix. Where terbutaline is used to provide a bronchodilator effect, the daily amount to be delivered is generally about 1 to about 20 mg., preferably about 1 mg. With ephedrine a decongestant effect is provided by delivering a daily amount of generally about 5 to about 30 mg., preferably about 20 mg. With clonidone an antihypertensive effect is provided by delivering a daily amount of generally about 0.2 to about 0.6 mg., preferably about 0.4 mg. With phenylephrine a decongestant effect is provided by delivering a daily amount of generally about 2 to about 50 mg. , perferably about 2.5 mg. With phenylpropanolamine bronchodilator and nasal decongestant effects are provided by delivering a daily amount of generally about 2 to about 50 mg. , preferably about 10 mg. With chlorpheniramine maleate an antihistaminic effect is provided by delivering a daily amount of generally about 1 to about 30 mg. , preferably about 3 mg. The estradiol esters used with this invention provide a uterine wall maintenance effect.
It will be appreciated that the above drugs may be added to the above mixture not only in the form of the pure chemical compound, but also in admixture with other drugs that may be transdermally applied or with other ingredients which are not incompatible with the desired objective of transdermally administering the drug to a patient. Thus, simple pharmacologically acceptable derivatives of the drugs such as ethers, esters, amides, acetals, salts, and the like may be used. With some drugs derivatives may actually be preferred.
The estradiol ester derivatives suitable for use according to this invention are pharmacologically acceptable esters particularly the 3-benzoate and 3-valerate esters of estradiol. Estradiol diacetate and other esters of a pharmocologically active type small enough to pass through the skin may also be used. The esters suitable for this invention provide a source of pharmacologically active estradiol in the
bloodstream. It must also be understood that the estradiol esters contemplated herein may be administered in admixture with other drugs which are not incompatible with the desired therapeutic objective.
The invention is illustrated by the following non-limiting Examples:
EXAMPLE I
Together there are mixed 30 gm. glycerol and 45 ml. water. This mixture is heated to 90°C; after reaching at least 70°C there are slowly added 15 gm. polyvinylalcohol (PVA 100% hydrolyzed, molecular weight 115,000) and 8 gm. polyvinylpyrrolidone (mw. 40,000). The mixture is stirred at 90°C until solution is effected, which may take about 10 minutes; it will be appreciated that with larger quantities, a considerably longer period of time may be needed. 98 ml. of this solution is then mixed with 2 gm. terbutaline, this mixture then being mechanically stirred until homogeneous. The homogeneous mixture is then poured into forms made of glass or stainless steel which serve as templates to produce a diffusion matrix having a thickness of about 2 to about 3 mm. This diffusion matrix is then cut into pieces with a total surface area suitable for the administration of a pharmaceutically effective amount of terbutaline.
The diffusion matrix is applied to the skin of a patient in need of a bronchodilator effect, the terbutaline being transdermally delivered to the skin of the patient. The diffusion matrix is ideally applied to the skin of the patient by means of a single-piece bandage having th'e diffusion matrix in the center under the occlusive layer, the bandage being provided to the patient with a peel-of cover much like a "band-aid" .
EXAMPLE II
In place of the glycerol of Example I , there is substituted 5 gm. polyethylene glycol having a molecular weight of 1000 and 25 ml. water. The resultant diffusion matrix is more
rigid than that of Example I.
EXAMPLE III In place of the glycerol of Example I, there is substituted 5 gm. polyethylene glycol (mw. 1,000), 4 gm. glycerol and 21 ml. water. The resultant diffusion matrix shares the improved rigidity of the diffusion matrix of Example II, while providing contact with the skin characteristic of the glycerol in this type of diffusion matrix.
EXAMPLE IV In place of the polyvinylalcohol and polyvinylpyrrilidone of Example I, there is substituted 2% by weight agarose, yielding a diffusion matrix for the transdermal delivery of terbutaline.
EXAMPLES V-XXIV Examples V-XXIV correspond to Examples I-IV, but for the substitution for terbutaline of the same amounts of the following drugs:
EXAMPLES DRUG
V-VIII ephedrine
IX-XII clonidine
XIII-XVI phenylephrine
XVII-XX phenylpropanolamine
XXI-XXIV chlorpheniramine maleate
Each of these drugs exhibits its characteristic therapeutic effect when administered via diffusion matrix.
EXAMPLE XXV Together there are mixed 20 gm. glycerol and 55 ml. water. This mixture is heated 90°C; after reaching at least 70 °C. There are slowly added 15 gm. polyvinylalcohol (PVA 100% hydrolyzed, molecular weight 115,000) and 8 gm. polyvinylpyrrolidone (mw. 40,000). The mixture is stirred at 90°C unitl solution is effected, which may take about 10 minutes; it will be appreciated that with larger guantities, a considerably longer period of time may be needed. 98 ml. of this solution is then mixed with 2 gm. estradiol diacetate, this
mixture then being mechanically stirred until homogeneous. The homogeneous mixture is then poured into forms made of glass or stainless steel which serve as templates to produce a diffusion matrix having a thickness of about 1 to 2 mm. This diffusion matrix is then cut into square pieces of about 1 inch on each side, i.e., to provide a total surface area of about 6.5 cm2.
The diffusion matrix is applied to the skin of a patient in need of uterine wall maintenance, the estradiol ester derivative being transdermally delivered. The diffusion matrix is ideally applied to the skin of the patient by means of a single-piece bandage having the diffusion matrix in the center under the occlusive layer, the bandage being provided to the patient with a peel-off cover much like a "band-aid".
EXAMPLE XXVI
Instead of casting the fluid homogeneous drug containing matrix with a 1 to 2 mm. thickness as disclosed in Example XXV, it is poured into oval forms 1 cm. thick. The cured diffusion matrix is applied in the form of a vaginal insert into a patient in need of uterine wall maintenance, the estradiol ester derivative being delivered in the vicinity of the cervix of the patient.
EXAMPLE XXVII
In place of the glycerol of Example XXV, there is substituted 10 gm. polyethylene glycol having a molecular weight of 1000 and 10 ml. water. The resultant diffusion matrix is more rigid than that of Example XXV, thus improving its ease of application in the form of a vaginal insert.
EXAMPLE XXVIII
In place of the glycerol of Example XXV, there is substituted 5 gm. polyethylene glycol (mw. 1000) , 4 gm. glycerol, and 11 ml. water. The resultant diffusion matrix shares the improved rigidity of the diffusion matrix of Example XXVII, while providing contact with the skin characteristic of the glycerol. This type of diffusion matrix is particularly
suitable for transdermal application.
EXAMPLE XXIX In place of the polyvinylalcohol and polyvinylpyrrolidone of Example XXV, there is substituted 2 gm. agarose and 21 ml. water, yielding a diffusion matrix for the delivery of estradiol ester derivative.
Claims
1. A self-supporting polymeric diffusion matrix for the sustained release of a drug selected from the group consisting of estradiol esters suitable for transdermal delivery phenylpropanolamine, chlorpheniramine maleate, clonidine, phenylephrine, terbutaline, and ephedrine in order to transdermally deliver said drug to a patient and provide said patient with a therapeutic effect, said matrix comprising from about 2 to about 60% of a polar plasticizer, from about 6 to about 20% by weight polyvinylalcohol, from about 2 to about 10% by weight polyvinylpyrrolidone, and a pharmaceutically effective amount of said drug to provide a sustained release of said drug over a prolonged period.
2. The polymeric diffusion matrix of claim 1 wherein said polar plasticizer is glycerol.
3. The polymeric diffusion matrix of claim 1 wherein said polyvinylalcohol has a molecular weight of about 50,000 to about 150,000.
4. The polymeric diffusion matrix of claim 1 wherein said polyvinylalcohol has a molecular weight of about 100,000 to about 150,000.
5. The polymeric diffusion matrix of claim 1 wherein said polyvinylpyrrolidone has a molecular weight of from about 15,000 to about 85,000.
6. The polymeric diffusion matrix of claim 1 wherein said polyvinylpyrrolidone has a molecular weight of about 20,000 to about 60,000.
7. The polymeric diffusion matrix of claim 1 wherein said polyvinylpyrrolidone has a molecular weight of 40,000 and said polyvinylalcohol has a molecular weight of 115,000.
8. The polymeric diffusion matrix of claim 1 wherein said polar plasticizer is polyethylene glycol present in an amount of about 2 to about 15% by weight.
9. The polymeric diffusion matrix of claim 1 wherein said polar plasticizer is a mixture of glycerol and polyethylene glycol wherein said polyethylene glycol is present in an amount by weight of from about 1 to about 5 parts per weight glycerol.
10. A method for the transdermal delivery of terbutaline to a patient to provide said patient with a bronchodilator effect, comprising applying to said patient a self-supporting diffusion matrix comprising from about 2 to about 60% by weight of a polar plasticizer, from about 6 to about 20% by weight polyvinylalcohol, from about 2 to about 10% by weight polyvinylpyrrolidone, and a pharmaceutically effective amount of terbutaline to provide a sustained release of said terbutaline over a prolonged period.
11. The method of claim 10 wherein said terbutaline is present in an amount to provide sustained release of about 1 to about 20 mg. per day.
12. A method for the transdermal delivery of ephedrine to a patient to provide said patient with a decongestant effect, comprising applying to said patient a self-supporting diffusion matrix comprising from about 2 to about 60% by weight of a polar plasticizer, from about 6 to about 20% by weight polyvinylalcohol, from about 2 to about 10% by weight polyvinylpyrrolidone, and a pharmaceutically effective amount of ephedrine to provide a sustained release of said ephedrine over a prolonged period.
13. The method of claim 12 wherein said ephedrine is present in an amount to provide sustained release of about 5 to about 20 mg. per day.
14. A method for the transdermal delivery of clonidine to a patient to provide said patient with a antihypertensive effect, comprising applying to said patient a self-supporting diffusion matrix comprising from about 2 to about 60% by weight of a polar plasticizer, from about 6 to about 20% by weight polyvinylalcohol, from about 2 to about 10% by weight polyvinylpyrrolidone, and a pharmaceutically effective amount of clonidine to provide a sustained release of said clonidine over a prolonged period.
15. The method of claim 14 wherein said clonidine is present in an amount to provide sustained release of about 0.2 to about 0.4 mg. per day.
16. A method for the transdermal delivery of phenylephrine to a patient to provide said patient with a decongestant effect, comprising applying to said patient a self-supporting diffusion matrix comprising from about 2 to about 60% by weight of a polar plasticizer, from about 6 to about 20% by weight polyvinylalcohol, from about 2 to about 10% by weight polyvinylpyrrolidone, and a pharmaceutically effective amount of phenylephrine to provide a sustained release of said phenylephrine over a prolonged period.
17. The method of claim 16 wherein said phenylephrine is present in an amount to provide sustained release of about 2 to about 50 mg. per day.
18. A method for the transdermal delivery of phenylpropanolamine to a patient to provide said patient with a bronchodilator effect, comprising applying to said patient a self-supporting diffusion matrix comprising from about 2 to about 60% by weight of a polar plasticizer, from about 6 to about 20% by weight polyvinylalcohol, from about 2 to about 10% by weight polyvinylpyrrolidone, and a pharmaceutically effective amount of phenylephrine to provide a sustained release of said phenylpropanolamine over a prolonged period.
19. The method of claim 18 wherein said phenylpropanolamine is present in an amount to provide sustained release of about 2 to about 50 mg. per day.
20. A method for the transdermal delivery of chlorpheniramine maleate to a patient to provide said patient with a antihistaminic effect, comprising applying to said patient a self-supporting diffusion matrix comprising from about 2 to about 60% by weight of a polar plasticizer, from about 6 to about 20% by weight polyvinylalcohol, from about 2 to about 10% by weight polyvinylpyrrolidone, and a pharmaceutically effective amount of chlorpheniramine maleate to provide a sustained release of said chlorpheniramine maleate over a prolonged period.
21. The method of claim 20 wherein said chlorpheniramine maleate is present in an amount to provide sustained release of about 1 to about 30 mg. per day.
22. A method for the transdermal delivery of estradiol esters suitable for transdermal delivery to a patient to provide said patient with a uterine wall maintenance effect, comprising applying to said patient a self-supporting diffusion matrix comprising from about 2 to about 60% by weight of a polar plasticizer, from about 6 to about 20% by weight polyvinylalcohol, from about 2 to about 10% by weight polyvinylpyrrolidone, and a physiologically effective amount of ari estradiol ester suitable for transdermal delivery to provide a sustained release of said estradiol ester suitable for transdermal delivery over a prolonged period.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU74151/81A AU7415181A (en) | 1980-07-09 | 1981-06-26 | Polymeric diffusion matrix for administration of drugs |
JP56502416A JPS57500980A (en) | 1980-07-09 | 1981-06-26 | |
PCT/US1981/000893 WO1982000099A1 (en) | 1980-07-09 | 1981-06-26 | Polymeric diffusion matrix for administration of drugs |
GB8206466A GB2089210B (en) | 1980-07-09 | 1981-06-26 | Polymeric diffusion matrix for administration of drugs |
DE813152182T DE3152182A1 (en) | 1980-07-09 | 1981-06-26 | POLYMERS DIFFUSION MATRIX FOR THE ADMINISTRATION OF MEDICINES |
NL8120270A NL8120270A (en) | 1980-07-09 | 1981-06-26 | Self-supporting polymeric diffusion matrix contg. terbutaline - comprising polar plasticiser, polyvinyl alcohol and polyvinyl pyrrolidone |
IT8219833A IT1237327B (en) | 1980-07-09 | 1982-02-24 | Polymeric diffusion matrix for administering drugs. |
SE8201337A SE447448B (en) | 1980-07-09 | 1982-03-04 | POLYMER DIFFUSION MATRIX FOR TRANSDERMAL ADMINISTRATION OF MEDICINAL PRODUCTS |
Applications Claiming Priority (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16700880A | 1980-07-09 | 1980-07-09 | |
US167008800709 | 1980-07-09 | ||
US167101 | 1980-07-09 | ||
US06/167,104 US4292302A (en) | 1979-08-14 | 1980-07-09 | Polymeric diffusion matrix containing terbutaline |
US167104 | 1980-07-09 | ||
US167106 | 1980-07-09 | ||
US06/167,101 US4294820A (en) | 1979-08-14 | 1980-07-09 | Polymeric diffusion matrix containing phenylephrine |
US167010 | 1980-07-09 | ||
US06/167,009 US4289749A (en) | 1979-08-14 | 1980-07-09 | Polymeric diffusion matrix containing phenylpropanolamine |
US06/167,010 US4292301A (en) | 1979-08-14 | 1980-07-09 | Polymeric diffusion matrix containing ephedrine |
US06/167,106 US4292303A (en) | 1979-08-14 | 1980-07-09 | Polymeric diffusion matrix containing clonidine |
US167729 | 1980-07-11 | ||
US06/167,729 US4291014A (en) | 1979-01-11 | 1980-07-11 | Polymeric diffusion matrix containing estradiol diacetate |
US217400 | 1980-12-17 | ||
US06/217,400 US4321252A (en) | 1979-08-14 | 1980-12-17 | Polymeric diffusion matrix containing ester derivatives of estradiol |
PCT/US1981/000893 WO1982000099A1 (en) | 1980-07-09 | 1981-06-26 | Polymeric diffusion matrix for administration of drugs |
US167009 | 1998-10-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1982000099A1 true WO1982000099A1 (en) | 1982-01-21 |
Family
ID=41698406
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1981/000893 WO1982000099A1 (en) | 1980-07-09 | 1981-06-26 | Polymeric diffusion matrix for administration of drugs |
Country Status (13)
Country | Link |
---|---|
JP (1) | JPS57500980A (en) |
AU (1) | AU7415181A (en) |
BE (1) | BE889549A (en) |
CA (1) | CA1163559A (en) |
CH (1) | CH658597A5 (en) |
DE (1) | DE3152182A1 (en) |
FR (1) | FR2486397A1 (en) |
GB (1) | GB2089210B (en) |
IT (1) | IT1237327B (en) |
NL (1) | NL8120270A (en) |
NO (1) | NO153638C (en) |
SE (1) | SE447448B (en) |
WO (1) | WO1982000099A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0095892A1 (en) * | 1982-05-26 | 1983-12-07 | Nippon Oil Co. Ltd. | Wound-covering materials |
FR2532546A1 (en) * | 1982-09-07 | 1984-03-09 | Biotrol Sa Lab | PASTE FOR SKIN PROTECTION |
EP0154907A2 (en) * | 1984-03-13 | 1985-09-18 | Bayer Ag | Medical wound dressing |
EP0237506A1 (en) * | 1986-02-14 | 1987-09-16 | Lejus Medical Aktiebolag | Pharmaceutical composition |
WO1989003859A1 (en) * | 1987-10-23 | 1989-05-05 | Vsesojuzny Nauchno-Issledovatelsky Institut Biotek | Composition of polymer diffusion matrix for transdermally introducing pharmaceutical substances |
US4860543A (en) * | 1986-08-08 | 1989-08-29 | Helix Technology Corporation | Vibration isolation system for a linear reciprocating machine |
DE4429667A1 (en) * | 1994-08-20 | 1996-02-22 | Lohmann Therapie Syst Lts | Estradiol TTS with water-binding additives |
WO2001043734A2 (en) * | 1999-12-16 | 2001-06-21 | Dermatrends, Inc. | Transdermal administration of phenylpropanolamine |
US6602912B2 (en) | 2000-06-30 | 2003-08-05 | Dermatrends, Inc. | Transdermal administration of phenylpropanolamine |
US6673363B2 (en) | 1999-12-16 | 2004-01-06 | Dermatrends, Inc. | Transdermal and topical administration of local anesthetic agents using basic enhancers |
US6719997B2 (en) | 2000-06-30 | 2004-04-13 | Dermatrends, Inc. | Transdermal administration of pharmacologically active amines using hydroxide-releasing agents as permeation enhancers |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2548021B1 (en) * | 1983-06-29 | 1986-02-28 | Dick P R | PROLONGED AND CONTINUOUS DERMAL PHARMACEUTICAL COMPOSITIONS BASED ON ESSENTIAL FATTY ACIDS |
IT1261305B (en) * | 1993-06-22 | 1996-05-14 | Gevipi Ag | VIBRATION AND NOISE DAMPING DEVICE, FOR HYDRAULIC SYSTEMS |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2693438A (en) * | 1951-02-21 | 1954-11-02 | Norwich Pharma Co | Preformed, nonadherent films for application to open lesions |
US2804073A (en) * | 1953-01-26 | 1957-08-27 | Protective Teatments Inc | Fluid surgical dressing |
US3214338A (en) * | 1964-07-31 | 1965-10-26 | Ehrlich Joseph Ronald | Medicament releasing film-forming ointments and process of making |
US3287222A (en) * | 1962-03-16 | 1966-11-22 | Roussel Uclaf | Method for preparation of synthetic fiber medical dressing impregnated with therapeutic |
GB1108837A (en) * | 1965-11-30 | 1968-04-03 | Astra Pharma Prod | Improvements in material for causing local anaesthesia |
US3577516A (en) * | 1969-12-02 | 1971-05-04 | Nat Patent Dev Corp | Preparation of spray on bandage |
US3608070A (en) * | 1969-06-10 | 1971-09-21 | Lucien Nouvel | New surgical dressing |
US3627871A (en) * | 1967-04-27 | 1971-12-14 | Boots Pure Drug Co Ltd | Therapeutic compositions for topical application |
SU219116A1 (en) * | 1965-11-26 | 1973-03-20 | А. А. Вишневский, Т. Т. Даурова, М. И. Долгина, И. А. Паников, Ф. П. Сидельковска , М. И. Шрайбер | FILM FOR PRIMARY PROCESSING OF THE BURN SURFACE |
US3803300A (en) * | 1970-03-18 | 1974-04-09 | H Pospischil | Ointment foil and method of preparing the same |
US3892905A (en) * | 1970-08-12 | 1975-07-01 | Du Pont | Cold water soluble plastic films |
US4210633A (en) * | 1978-10-20 | 1980-07-01 | Eli Lilly And Company | Flurandrenolide film formulation |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL59063A (en) * | 1979-01-11 | 1983-12-30 | Key Pharma | Polymeric diffusion matrix for release of pharmaceutical dosage |
-
1981
- 1981-06-24 CA CA000380505A patent/CA1163559A/en not_active Expired
- 1981-06-26 NL NL8120270A patent/NL8120270A/en unknown
- 1981-06-26 GB GB8206466A patent/GB2089210B/en not_active Expired
- 1981-06-26 AU AU74151/81A patent/AU7415181A/en not_active Abandoned
- 1981-06-26 CH CH1456/82A patent/CH658597A5/en not_active IP Right Cessation
- 1981-06-26 WO PCT/US1981/000893 patent/WO1982000099A1/en active Application Filing
- 1981-06-26 JP JP56502416A patent/JPS57500980A/ja active Pending
- 1981-06-26 DE DE813152182T patent/DE3152182A1/en not_active Withdrawn
- 1981-07-08 BE BE0/205347A patent/BE889549A/en not_active IP Right Cessation
- 1981-07-09 FR FR8113518A patent/FR2486397A1/en active Pending
-
1982
- 1982-02-24 IT IT8219833A patent/IT1237327B/en active
- 1982-03-04 SE SE8201337A patent/SE447448B/en not_active IP Right Cessation
- 1982-03-08 NO NO820722A patent/NO153638C/en unknown
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2693438A (en) * | 1951-02-21 | 1954-11-02 | Norwich Pharma Co | Preformed, nonadherent films for application to open lesions |
US2804073A (en) * | 1953-01-26 | 1957-08-27 | Protective Teatments Inc | Fluid surgical dressing |
US3287222A (en) * | 1962-03-16 | 1966-11-22 | Roussel Uclaf | Method for preparation of synthetic fiber medical dressing impregnated with therapeutic |
US3214338A (en) * | 1964-07-31 | 1965-10-26 | Ehrlich Joseph Ronald | Medicament releasing film-forming ointments and process of making |
SU219116A1 (en) * | 1965-11-26 | 1973-03-20 | А. А. Вишневский, Т. Т. Даурова, М. И. Долгина, И. А. Паников, Ф. П. Сидельковска , М. И. Шрайбер | FILM FOR PRIMARY PROCESSING OF THE BURN SURFACE |
GB1108837A (en) * | 1965-11-30 | 1968-04-03 | Astra Pharma Prod | Improvements in material for causing local anaesthesia |
US3627871A (en) * | 1967-04-27 | 1971-12-14 | Boots Pure Drug Co Ltd | Therapeutic compositions for topical application |
US3608070A (en) * | 1969-06-10 | 1971-09-21 | Lucien Nouvel | New surgical dressing |
US3577516A (en) * | 1969-12-02 | 1971-05-04 | Nat Patent Dev Corp | Preparation of spray on bandage |
US3803300A (en) * | 1970-03-18 | 1974-04-09 | H Pospischil | Ointment foil and method of preparing the same |
US3892905A (en) * | 1970-08-12 | 1975-07-01 | Du Pont | Cold water soluble plastic films |
US4210633A (en) * | 1978-10-20 | 1980-07-01 | Eli Lilly And Company | Flurandrenolide film formulation |
Non-Patent Citations (2)
Title |
---|
Chemical Abstracts, Volume 79, No. 8, Issued 27 August 1973 (Columbus, Ohio, USA) A.A. Vishnevski et al; PROTECTIVE AND MEDICATED FILM FOR THE INITIAL TREATMENT OF SCALDS, Page 215, column 2, the abstract No. 45845b; & SU-A-219 116 20 March 1973 * |
Vishnevski, A.A., et al; & SU-A-219 116, 20 March 1973, from OTKRYTIYA IZOBRET, PROM. OBRAZTSY, TOVARNY ZNAKI 1973 50(15), 170. * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0095892A1 (en) * | 1982-05-26 | 1983-12-07 | Nippon Oil Co. Ltd. | Wound-covering materials |
FR2532546A1 (en) * | 1982-09-07 | 1984-03-09 | Biotrol Sa Lab | PASTE FOR SKIN PROTECTION |
EP0107526A1 (en) * | 1982-09-07 | 1984-05-02 | Laboratoires Biotrol S.A. | Paste for protecting the skin |
US4503034A (en) * | 1982-09-07 | 1985-03-05 | Laboratoires Biotrol S.A | Paste for protecting the skin |
EP0154907A2 (en) * | 1984-03-13 | 1985-09-18 | Bayer Ag | Medical wound dressing |
EP0154907A3 (en) * | 1984-03-13 | 1986-02-12 | Bayer Ag | Medical wound dressing |
US4738670A (en) * | 1984-03-13 | 1988-04-19 | Bayer Aktiengesellschaft | Medicinal plasters |
EP0237506A1 (en) * | 1986-02-14 | 1987-09-16 | Lejus Medical Aktiebolag | Pharmaceutical composition |
US4860543A (en) * | 1986-08-08 | 1989-08-29 | Helix Technology Corporation | Vibration isolation system for a linear reciprocating machine |
WO1989003859A1 (en) * | 1987-10-23 | 1989-05-05 | Vsesojuzny Nauchno-Issledovatelsky Institut Biotek | Composition of polymer diffusion matrix for transdermally introducing pharmaceutical substances |
DE4429667A1 (en) * | 1994-08-20 | 1996-02-22 | Lohmann Therapie Syst Lts | Estradiol TTS with water-binding additives |
WO2001043734A2 (en) * | 1999-12-16 | 2001-06-21 | Dermatrends, Inc. | Transdermal administration of phenylpropanolamine |
WO2001043734A3 (en) * | 1999-12-16 | 2002-01-03 | Dermatrends Inc | Transdermal administration of phenylpropanolamine |
US6673363B2 (en) | 1999-12-16 | 2004-01-06 | Dermatrends, Inc. | Transdermal and topical administration of local anesthetic agents using basic enhancers |
US6602912B2 (en) | 2000-06-30 | 2003-08-05 | Dermatrends, Inc. | Transdermal administration of phenylpropanolamine |
US6719997B2 (en) | 2000-06-30 | 2004-04-13 | Dermatrends, Inc. | Transdermal administration of pharmacologically active amines using hydroxide-releasing agents as permeation enhancers |
Also Published As
Publication number | Publication date |
---|---|
GB2089210A (en) | 1982-06-23 |
NO820722L (en) | 1982-03-08 |
DE3152182A1 (en) | 1983-02-10 |
IT1237327B (en) | 1993-05-31 |
SE8201337L (en) | 1982-03-04 |
JPS57500980A (en) | 1982-06-03 |
NO153638C (en) | 1986-05-07 |
CH658597A5 (en) | 1986-11-28 |
CA1163559A (en) | 1984-03-13 |
SE447448B (en) | 1986-11-17 |
BE889549A (en) | 1981-11-03 |
NO153638B (en) | 1986-01-20 |
AU7415181A (en) | 1982-02-02 |
GB2089210B (en) | 1984-09-05 |
IT8219833A0 (en) | 1982-02-24 |
FR2486397A1 (en) | 1982-01-15 |
NL8120270A (en) | 1982-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4472372A (en) | Polymeric diffusion matrix containing chlorpheniramine maleate | |
US4291014A (en) | Polymeric diffusion matrix containing estradiol diacetate | |
US4460562A (en) | Polymeric diffusion matrix containing propranolol | |
US4438139A (en) | Polymeric diffusion matrix containing estrogens | |
US5686097A (en) | Monoglyceride/lactate ester permeation enhancer for codelivery of steroids | |
US10238612B2 (en) | Transdermal administration of tamsulosin | |
US5900247A (en) | Mucoadhesive pharmaceutical composition for the controlled release of active principles | |
JP2974969B2 (en) | Solid matrix system for transdermal drug delivery | |
KR20220082928A (en) | Transdermal formulation and delivery method of low solubility or unstable unionized neutral drugs by in situ salt-to-neutral drug conversion of salt drug | |
IE50567B1 (en) | Polymeric diffusion matrix | |
WO1982000099A1 (en) | Polymeric diffusion matrix for administration of drugs | |
AU2007200426A1 (en) | Transdermal delivery of lasofoxifene | |
EP0483370B1 (en) | Percutaneous preparation containing estradiol | |
US4482533A (en) | Polymeric diffusion matrix containing propranolol | |
JPH03275619A (en) | External agent composition | |
WO1982000005A1 (en) | Polymeric diffusion matrix containing a vasodilator | |
JP3295735B2 (en) | Estriol transdermal patch | |
WO1983000092A1 (en) | Polymeric diffusion matrix containing propranolol | |
EP0083370A1 (en) | Polymeric diffusion matrix containing 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile | |
TWI298253B (en) | Transdermal delivery of lasofoxifene | |
JP2017226618A (en) | Percutaneously absorbable formulation of leuprorelin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Designated state(s): AT AU CH DE DK GB JP NL NO SE Kind code of ref document: A1 Designated state(s): AT AU CH DE DK GB JP NL NO SE |
|
RET | De translation (de og part 6b) |
Ref document number: 3152182 Country of ref document: DE Date of ref document: 19830210 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3152182 Country of ref document: DE |